Autologous Mesenchymal Stem Cell and Islet Cotransplantation: Safety and Efficacy

HONGJUN WANG, CHARLIE STRANGE, PAUL J. NIETERT, JINGJING WANG, TAYLOR L. TURNBULL, COLLEEN CLOUD, STEFANIE OWZARSKY, BETSY SHUFORD, TARA DUKE, GARY GILKESON, LOUIS LUTTRELL, KATHIE HERMAYER, JYOTIKA FERNANDES, DAVID B. ADAMS, KATHERINE A. MORGAN

Key Words. Bone marrow • Cell death • Chronic pancreatitis • Glycemic control • Islet transplantation • Mesenchymal stem cell

ABSTRACT

Islet engraftment after transplantation is impaired by high rates of islet/β cell death caused by cellular stressors and poor graft vascularization. We studied whether cotransplantation of ex vivo expanded autologous bone marrow-derived mesenchymal stem cells (MSCs) with islets is safe and beneficial in chronic pancreatitis patients undergoing total pancreatectomy with islet autotransplantation. MSCs were harvested from the bone marrow of three islet autotransplantation patients and expanded at our current Good Manufacturing Practices (cGMP) facility. On the day of islet transplantation, an average dose of 20.0 ± 2.6 × 10^6 MSCs was infused with islets via the portal vein. Adverse events and glycemic control at baseline, 6, and 12 months after transplantation were compared with data from 101 historical control patients. No adverse events directly related to the MSC infusions were observed. MSC patients required lower amounts of insulin during the peritransplantation period (p = .02 vs. controls) and had lower 12-month fasting blood glucose levels (p = .02 vs. controls), smaller C-peptide declines over 6 months (p = .01 vs. controls), and better quality of life compared with controls. In conclusion, our pilot study demonstrates that autologous MSC and islet cotransplantation may be a safe and potential strategy to improve islet engraftment after transplantation. (Clinicaltrials.gov registration number: NCT02384018). STEM CELLS TRANSLATIONAL MEDICINE 2018;7:11–19

SIGNIFICANCE STATEMENT

This pilot study demonstrates for the first time that intrahepatic infusion of autologous bone marrow-derived mesenchymal stem cells (MSCs) during islet transplantation may be safe and may have the potential to improve islet engraftment, glycemic control, and quality of life. This work extends the current paradigm of MSCs as an immune regulatory factor and reveals important additional functions of MSCs in promoting islet engraftment after transplantation in islet autotransplant patients. This study proves justification for a larger and randomized clinical trial, as MSCs have the potential to reduce inflammatory damage and support angiogenesis in transplanted islets.

INTRODUCTION

Autologous islet transplantation is currently performed in patients with chronic pancreatitis (CP) to avoid type 1c diabetes after total pancreatectomy. Allogeneic islet transplantation offers promising therapy for patients with type 1 diabetes. The long-term efficiency and effectiveness of islet transplantation are problematic. Stresses induced during islet harvesting and after transplantation led to death of more than half of the transplanted islets even under optimal conditions [1, 2]. Numerous factors including the instant blood-mediated inflammatory reaction (IBMIR), proinflammatory cytokines, and hypoxia contribute to poor islet engraftment and β cell death during the peritransplantation period [3–6]. Engrafted islets may be further destroyed by chronic β cell exhaustion and autoimmune responses, which decreases the survival and function of transplanted islets and eventually leads to impaired glycemic control in patients. Insulin independent rates are known to be low in both autologous and allogeneic islet recipients [3, 7–10]. Strategies that can increase islet engraftment after transplantation may enhance the effectiveness of islet transplantation [11, 12].

Mesenchymal stem cells (MSCs) are adult stem cells that can be harvested from bone marrow, adipose, and dental pulp. They attach to standard plastic cell culture plates, express specific cellular markers such as CD73, CD90, and CD105, and can be differentiated into osteoblasts,
adipocytes, and chondroblasts [13]. They possess a remarkably diverse array of tissue protective and immunosuppressive characteristics [14–18].

In murine models of diabetes, systemic infusion of MSCs delays the onset of diabetes, improves glycemic control, promotes pancreatic tissue regeneration, reduces pancreatic insulitis, and prevents autoimmune destruction [17, 19, 20]. Intravenously infused MSCs are known to migrate to pancreatic islets or the injured pancreas [21, 22].

The immunological properties of MSCs show great potential in organ transplant therapies and are associated with lower rates of organ rejection and infection following transplant. Cotransplantation of MSCs and islets protects the islets from injury in rodent models. In streptozotocin (STZ)-induced diabetic mice, cotransplantation of syngeneic MSCs with a marginal mass of allogeneic islets under the kidney capsule resulted in prolonged normoglycemia [23]. In the STZ-induced diabetic rodents, cotransplantation of syngeneic MSC in the omentum [24] and kidney capsule [23, 25, 26] significantly prolonged islet graft survival compared with animals receiving islets alone. In nonhuman primates, intraportal cotransplantation of donor MSCs and islets in an allogeneic islet transplantation setting provided a distinct advantage in promoting early islet engraftment [27].

The major mechanism of MSC protection may be in their paracrine secretion of protective factors [27, 28]. MSCs promote angiogenesis based on their ability to secrete vascular endothelial growth factor, hepatocyte growth factor, TGF-β and others. These factors are required for angiogenesis, and local increase in concentration by MSCs may improve islet implantation [29–31]. Based on these attributes, we hypothesize that cotransplantation of autologous MSCs can enhance islet engraftment, survival, and function in CP patients undergoing islet autotransplantation (IAT).

MSCs are currently being tested in clinical trials for the treatment of type 1 and type 2 diabetes, diabetes complications, and other diseases (clinicaltrials.gov). A recent survey indicated that more than 1,000 humans have received MSCs for various indications. No adverse events (AEs) during or after MSC infusion have been reported, and no ectopic tissue formation has been noted [32]. We have validated that the phenotype and functional integrity of MSCs from CP patients are comparable to those from healthy donors (Wang, unpublished data), suggesting that MSCs from CP patients are suitable for cellular therapy. In this pilot clinical trial, we evaluated the safety and efficacy of cotransplantation of autologous MSCs and islets in patients who undergo total pancreatectomy and islet transplantation (TP-IAT). We compared adverse events, glycemic control, and quality of life (QOL) of MSC treated patients with 101 matched historical patients who received islet transplantation alone.

**Materials and Methods**

**Patient Selection**

Diabetes-free adult chronic pancreatitis patients scheduled for total pancreatectomy with islet autotransplantation were enrolled in this case-control study. Participants were enrolled if they had normal renal function, normal coagulation parameters, and normal liver function as measured by serum levels of alanine aminotransferase, aspartate aminotransferase, and total bilirubin. Patients who had undergone prior transduodenal sphincteroplasty or pancreatic head resection procedures were eligible for enrollment, but other resection or pancreatic drainage procedures precluded enrollment. All patients signed informed consent approved by the Medical University of South Carolina (MUSC) Institutional Review Board. The clinicaltrial.gov registration number is NCT02384018.

**Study Design**

This study was designed as a phase I, open-label, single-center, pilot study to evaluate the safety and efficacy of cotransplantation of autologous bone marrow-derived MSCs with islets in CP patients undergoing TP-IAT. The safety and efficacy of infusion of MSCs immediately after islet transplantation were assessed through adverse events, onset of diabetes, glycemic control, pain relief, and quality of life indexes. Data were compared with those from 101 adult patients who were diabetes-free prior to surgery and had TP-IAT at MUSC from 2009 to 2015 who completed 6- and 12-month follow-up visits.

**MSC Preparation**

A bone marrow aspirate (10–15 ml) was harvested from the iliac crest from patients under local anesthesia 21 days before scheduled islet transplantation. Samples were placed on ice and transferred to the MUSC class 10,000 current Good Manufacturing Practice (cGMP) compliant clean room. Bone marrow mononuclear cells (MNCs) were isolated by Ficoll density gradient (density 1.077 g/cm³) centrifugation. Washed cells were resuspended in serum-free alpha-MEM supplemented with gentamicin (VWR, Radnor, PA, USA, https://us.vwr.com/store/). MNCs were plated at a density of 10,000–20,000 cells/cm². Cells were cultured in alpha-MEM supplemented with pooled human platelet lysate (from Emory University) at 37°C in a humidified atmosphere containing 5% CO₂. When the cultures reach near confluence (>80%), cells were detached by treatment with TrypLE (Gibco, Gaithersburg, MD, USA, https://www.thermofisher.com/us/en/home/brands/gibco.html) and re-plated at a density of 1,000 cells/cm² in flasks. MSCs at passage 4 were used for transplantation. Release criteria of MSCs were as follows: (>95%) CD73, CD90, CD105, and (<5%) for CD14, CD31, CD45 and HLA-DR, viability >70% (by Trypan blue dye exclusion assay), negative gram stain of the infusion product, negative bacterial, fungal, endotoxin, and mycoplasma tests. We obtained an average of 26 ± 9.7 × 10⁶ MSCs at passage 4. Cells were resuspended into 4 × 10⁶ cells/ml in Plasmalyte A for infusion. Each patient received 20 × 10⁶ (± 15%) cells without heparin. The number of MSCs infused was determined based on numbers of MSCs used in other clinical trials and a nonhuman primate study in which MSCs and islet were cotransplanted into streptozotocin-induced diabetic cynomolgus monkeys [27].

**Islet Harvest and Transplantation**

The pancreatectomy was performed by open laparotomy at the MUSC Hospital. After devascularization, the pancreas was transferred to the MUSC cGMP facility where islets were harvested from the pancreas using the modified Ricordi method [33]. Total unpurified islets were resuspended in 5% human albumin with heparin (70 U/kg body weight) for infusion. Endotoxin assays, gram stains, and bacterial and fungal cultures were measured in the final products and used as sterility indicators. Non-purified islets were infused into the portal vein via the mesenteric vein of the patient who was under general anesthesia. MSCs were infused right after islet infusion via the same route. No other
anticoagulation was used during and after islet infusion. Hepatic pressures were measured before, during, and after infusion.

Safety Tests
Patients were put on insulin treatment for a target glucose level of 100 mg/dl during the perioperative period before being discharged. All AEs were recorded and classified according to their severity. The independent Data Safety Monitoring Committee (DSMB) reviewed serious AEs (SAEs). All autologous islet transplant patients are scheduled to return to MUSC at 1, 2, 3, and 6 months, and then yearly for checkup after hospital discharge.

Measurement of Clinical Outcomes
Diabetes onset and insulin requirements after surgery were measured and compared between groups. Fasting plasma glucose, C-peptide, hemoglobin A1C (HbA1c), and indexes from a mixed-meal tolerance test (MMTT) including serum C-peptide levels evaluated glycemic control. Insulin independence was defined [34] as no-insulin therapy, HbA1c <6.5%, fasting blood glucose <126 mg/dl and 2 h postprandial blood glucose <180 mg/dl.

MMTT
The MMTT was performed at 6 months postoperatively. Patients were asked to drink “BOOST,” which contains a mixture of protein, fat and carbohydrates, at a dose of 6 mL per kilogram body weight after fasting overnight. Patient’s blood was drawn prior to the BOOST and then at 15, 30, 60, 90, 120, 180, and 240 minutes (±5 minutes) after ingestion. Glucose and C-peptide levels in serum were measured using standard methods. The mixed meal stimulation index was calculated as described [35], and results were compared with the only four historical patients who had done the MMTT.

Statistics
Two-tailed independent sample t tests were used to compare mean differences between groups, and variances were conservatively assumed to be unequal. Glucose and C-peptide values after MMTT over time were compared between groups using general linear mixed models. All values are presented as mean and standard deviation unless otherwise specified. p < .05 was denoted as statistically significant.

RESULTS
Characteristics of Patients
We report on the first three patients who received MSCs as part of their islet autotransplantation and compared demographic variables with the 101 historical patients referred as “CTRs”. There were no significant differences in demographic variables, including patient age, body weight, body mass index, HbA1c, and years of chronic pancreatitis (Table 1). MSCs were collected and ex vivo expanded for 21 days prior to scheduled islet transplantation (Fig. 2A). No differences in islet product weight, total islet equivalent numbers (IEQ) infused, and IEQ transplanted per kilogram of body weight were seen. MSC patients received an average of 20.0 ± 2.6 × 10^7 MSCs (Table 1). The total volume of cells infused was 5.36 ± 0.75 ml. Hepatic pressures increased to similar degrees after infusion in both MSC and CTR patients (Table 1).

AEs and SAEs
Adverse events are summarized in Table 2. All three patients who received MSCs tolerated the procedure well. The first patient did not have any AE. The second patient had dehydration, bacterial pneumonia, a pleural effusion, and a positive purified protein derivative. This patient was also treated for a possible non-occlusive portal vein thrombosis (PVT). The diagnosis was suggested by a contrasted dual phase computed tomography image that showed a filling defect not observed at the time of follow-up visits. The possibility of incomplete contrast timing could not be excluded. The third patient had emesis, upper gastrointestinal bleeding and left PVT. All AEs and SAEs resolved within 8 weeks. All of the above AEs have also been observed in historical control

Table 1. Patient characteristics at diagnosis and islet and MSC infusion

| Characteristics | Patient 1 | Patient 2 | Patient 3 | Mean | SD | Mean | SD | p value |
|-----------------|-----------|-----------|-----------|------|----|------|----|---------|
| Age (yr)        | 26        | 29        | 46        | 33.7 | 10.8 | 42.4 | 11.4 | .29     |
| Body weight (kg)| 76        | 109       | 79        | 88.0 | 18.2 | 74.4 | 20.6 | .33     |
| BMI (kg/m²)     | 23        | 44        | 25        | 30.7 | 11.6 | 26.4 | 6.3  | .59     |
| HbA1C pre-op (%)| 5.4       | 5.6       | 5.4       | 5.5  | 0.1  | 5.7  | 0.9  | .11     |
| Years of CP     | 9         | 11        | 10        | 10.0 | 1.0  | 8.2  | 5.8  | .06     |
| Islet product weight (g) | 7 | 50 | 30 | 29.0 | 21.5 | 15.6 | 11.9 | .39 |
| Total islet infused IEQ | 221,124 | 704,244 | 470,888 | 465,152 | 241,598 | 277,986 | 221,211 | .31 |
| IEQ/kg          | 2,909     | 6,461     | 5,950     | 5,107 | 1,920 | 3,863 | 3,127 | .38     |
| MSC (×10^6)     | 22        | 17        | 21        | 20.0 | 2.6  | 0    | 0    | N/A     |

Hepatic pressure (mmHg)

| Pre-infusion | 7 | 11 | 6 | 8 | 2.6 | 7.9 | 3.6 | N/A |
| During infusion | 7 | 19 | 13 | 13 | 6 | 13 | 5.8 | N/A |
| Post-infusion | 8 | 29 | 16 | 17.7 | 10.6 | 16 | 8.3 | N/A |

Abbreviations: BMI, body mass index; CP, chronic pancreatitis; HbA1c, hemoglobin A1C; IEQ, islet equivalent number; MSC, mesenchymal stem cell; N/A, not applicable; yr, years; SD, standard deviation.
No PVT (n=92) PVT (n=8) 

\[ p = .0004 \]

**Table 2. Adverse events of MSC patients**

| Subject ID | AE Description          | Start Date | End Date | Severity | Casual Relationship | Action Taken | SAE? | SAE Reason | Outcome |
|------------|-------------------------|------------|----------|----------|---------------------|--------------|------|------------|---------|
| MSC1       | None                    |            |          |          |                     |              |      |            |         |
| MSC2       | Dehydration             | 4/1/15     | 4/13/15  | 1        | 1                   | 2            | Y    | 2          | 1       |
| MSC2       | Portal vein thrombosis  | 4/22/15    |          | 1        | 1                   | 2            | Y    | 6          | 1       |
| MSC2       | Pneumonia               | 4/29/15    | 5/1/15   | 1        | 1                   | 2            | Y    | 2          | 1       |
| MSC2       | Pleural effusion        | 6/20/15    | 6/26/15  | 1        | 1                   | 2            | Y    | 2          | 1       |
| MSC2       | Latent TB infection/w/fever | 7/15/15 | 7/26/15  | 1        | 1                   | 1            | Y    | 2          | 1       |
| MSC2       | Right pleural effusion  | 8/19/15    | 8/20/15  | 1        | 1                   | 1            | Y    | 2          | 1       |
| MSC3       | Left portal vein thrombosis | 6/1/15 | 6/20/15  | 1        | 1                   | 2            | Y    | 6          | 1       |
| MSC3       | Emesis                  | 6/11/15    | 6/18/15  | 1        | 1                   | 2            | Y    | 2          | 1       |
| MSC3       | Upper GI bleed          | 6/11/15    | 6/18/15  | 3        | 1                   | 3            | Y    | 2          | 1       |

**Key**

| Severity | Casual Relationship | Action Taken | SAE Reason | Outcome |
|----------|---------------------|--------------|------------|---------|
| Grade 1  | Mild                | None         | Life-threatening | 1       |
| Grade 2  | Moderate            | Unlikely     | Medication  | 2       |
| Grade 3  | Severe              | Possibly     | Other       | 3       |
| Grade 4  | Life-threatening    | Probably     | Resulting in persistent significant disability or incapacity | 4       |
| Grade 5  | Death               |              |             | 5       |

**Abbreviations:** AE, adverse event; GI, gastrointestinal; MSC, mesenchymal stem cell; SAE, serious adverse events; TB, tuberculosis; Y, yes.

**Figure 1.** Patients who had PVT showed higher average islet pellet weight compared with patients without PVT. Islet pellet weights in patients who had PVT or didn’t have PVT (no-PVT) after islet transplantation. Error bars represent standard errors; \( p \) values are from Student’s \( t \) test assuming unequal variances. Abbreviation: PVT, portal vein thrombosis.

Mesenchymal Stem Cell and Islet Cotransplantation

Patients was insulin-free, compared with 22.2% and 20.0% of historical control patients at 6 and 12 months, respectively (Fig. 2B). MSC patients required less daily insulin than historical controls on postoperative day 2 (10.7 ± 4.5 U vs. 22.0 ± 18.7 U, MSC: control, \( p = .02 \)) and day 3 (5.3 ± 6.1 U vs. 18.7 ± 19.1 U, \( p = .04 \)). Daily exogenous insulin usages still trended lower in MSC group at 6 months (9.3 ± 8.1 U vs. 18.1 ± 21.5 U, \( p = .19 \)) and 12 months postoperatively (16.7 ± 15.0 U vs. 20.7 ± 23.1 U, \( p = .69 \); Fig. 2C).

There was no difference in fasting blood glucose levels preoperatively. However, MSC patients had lower fasting blood glucose levels compared with controls at both 6 months (114.3 ± 28.4 mg/dl vs. 165.3 ± 95.2 mg/dl, \( p = .06 \)) and 12 months (113.7 ± 26.0 mg/dl vs. 182.1 ± 110.8 mg/dl, \( p = .02 \); Fig. 2D). No differences in HbA1c levels were observed between MSC patients and controls at any time (Fig. 2E). Patients in the historical group had significantly higher C-peptide levels preoperatively compared with MSC patients (0.32, \( p < .001 \)). However, the 6-month mean C-peptide decline of controls dropped 1.5 ± 2.7 ng/ml, while C-peptide levels in MSC group dropped 0.4 ± 0.4 ng/ml (\( p = .01 \); Fig. 2F).

Mixed meal tolerance tests were performed in the MSC and 4 historical control patients at 6 months postoperatively. There was no difference in peak C-peptide level during the MMTT (2.2 ± 2.3 ng/ml vs. 1.9 ± 0.9 ng/ml, MSC vs. CTR, \( p = .87 \); Fig. 3A, 3B), C-peptide area under the curve (24.9 ± 11.2 vs. 17.7 ± 19.5, MSC vs. CTR, \( p = .5 \); Fig. 3C), or Mixed Meal Stimulation Index (0.36 ± 0.22 vs. 0.22 ± 0.32, MSC vs. CTR, \( p = .5 \)) between MSC and control populations, respectively (Fig. 3D).
One in 3 patients in the MSC group required narcotics for long-term pain relief, compared with 79% and 74% of the historical controls at both 6 and 12 months, respectively. MSC patients required much less morphine and equivalent at both time points (Fig. 4A). MSC patients showed significantly higher physical QOL with better pain relief at 6 months compared with controls (Fig. 4B, 4C). There were no differences in psychological QOL between MSC and control patients (Fig. 4D).

DISCUSSION

Although limited in the number of patients treated, our pilot study demonstrates for the first time that intrahepatic infusion of autologous bone marrow-derived MSCs during islet transplantation may be safe and may have the potential to improve islet engraftment, glycemic control, and quality of life. This work extends the current paradigm of MSCs as an immune regulatory factor and reveals important additional functions of MSCs in promoting islet engraftment after transplantation in TP-IAT patients.

It seems that MSC infusion via the portal vein was safe and well tolerated by our three islet transplant patients. Increasing numbers of clinical trials are evaluating the therapeutic effects of MSC in a wide range of diseases and conditions related to autoimmune disorders, inflammatory diseases, and regenerative disorders. Data from MSC-treated patients have demonstrated the safety of this procedure [36]. Safety is particularly difficult to assess following an operation with known major morbidity such as pancreatectomy. Therefore, we relied on the independent DSMB to adjudicate all events as related or not related to MSC infusion. One of the common complications of islet transplantation is PVT. The slowed portal vein flow by cellular occlusion is in part responsible, and this complication may be related to the volume of cells infused into the portal vein. It has been reported that higher islet tissue volume is associated with higher portal pressure and complications during autologous islet transplantation [37]. We also found that PVT occurrence is positively correlated with islet pellet weight (Fig. 1) and hepatic pressure (Table 1). Because Patients 2 and 3 in the MSC group had high pellet weights and
higher hepatic pressures during product infusion, they had higher chance of PVT. In future studies, purification may be used to reduce the total islet tissue volume and the complications it may cause [37]. Whether MSC infusion increases the chance of thrombosis is controversial since these cells are significantly smaller than islets. However, microvascular obstruction after intracoronary delivery has been described [38]. In addition, MSCs may have innate procoagulant activity. One previous study showed that cultured MSCs trigger an IBMIR when injected in a higher dose ($>1 \times 10^7$ per kg) [39]. Other studies indicate that local MSC injection may restore a thrombosed vein by clot recanalization and may stimulate angiogenesis [40]. Although studies have shown that partial thrombosis did not affect islet function [41], further studies with more patients are needed to exclude the possibility that MSC infusion increases the chance of thrombosis in islet transplantation patients.

Another finding of this study is that MSC infusion improved glycemic control in CP patients. Although we did not observe differences in Hba1c and C-peptide levels, MSC patients required less exogenous insulin and had lower blood glucose levels at 12 months. Tempering the enthusiasm is the heterogeneity of 6-month MMTT responses that will need much larger cohorts to define the correlates of islet cell survival and function.

Two potential mechanisms might have contributed to the improvement in glycemic control. First, as suggested in the nonhuman primate and mouse islet transplantation models, MSC cotransplantation increased islet engraftment by inhibition of islet cell death and enhanced graft revascularization after transplantation [27]. Second, infused MSCs increased insulin sensitivity in IAT patients and therefore led to a better glycemic control, as observed in mouse models of obesity and diabetes [42]. In addition, MSC might also have played a role in pain relief and therefore quality of life in this patient population, as observed in other studies [43, 44]. Further studies are needed to test this possibility.

In addition to the small cohort size, a major limitation of this study is the large difference in islet number and islet numbers per kg body weight transplanted between MSC patients and controls. Several studies showed a positive correlation between high islet cell yields and postoperative insulin independence [45, 46]. When initial yields are high, islets are subject to damage and loss during and after transplantation.

There are still many unanswered questions that can be resolved in further trials. The first is to determine an ideal number of MSC needed for the islet transplant patients. Although the large number and types of currently registered MSC clinical trials highlight the safety and tolerability of MSC infusions, the ideal dosage of MSC for a certain disease is unknown. In graft versus host disease trials, patients have been given intravenous doses of $10^6$ cells/kg MSCs [47]. In Crohn’s disease, patients have received intravenous infusions of allogeneic MSCs ($2 \times 10^6$ cells/kg body weight) weekly for 4 weeks [48]. In an allogeneic islet transplantation model in the nonhuman primate, $5 \times 10^6$ MSCs were mixed with 10,000–20,000 IEQ islets and cotransplanted intraportally into recipients. The islet cell and MSC ratios ranged from 3.7 to 13.4 [27]. The MSCs we used were autologous in nature, delivered fresh, and not cryopreserved as in other studies. By delivering autologous cells, we hoped to prolong MSC survival in our patients and produce a better clinical response. Another
The benefit of delivering fresh cells is that they are more metabolically active than those being thawed and infused at the bedside, and, consequently, DMSO-associated side effects following infusion would be absent.

The duration of MSC survival and ultimate differentiation pathways remain unknown in humans. In the allogeneic nonhuman primate study, MSCs injected via the portal vein were observed in the pancreas and lung of one monkey but not the other at 1 month after cell infusion [27]. In lupus patients, the beneficial effect of MSC lasted from 6 months to >2 years after infusion of MSC [49]. In the future, it will be possible to study cell trafficking by the infusion of labeled cells with cell tracer.

The mechanisms by which MSCs confer islet protection also remain unknown. As shown in a nonhuman primate islet transplantation model, the most probable mechanism is that MSCs stay in proximity to islets at the time of transplantation and provide vascularization and regenerative signals that contribute to graft survival [27]. The local balance of the proinflammatory and anti-inflammatory microenvironment may be altered, as is suggested in other diseases [50]. In addition, MSCs cotransplanted with islets have the potential to differentiate into insulin-secreting cells, because MSCs have high plasticity. This has been shown in diabetic rat models in vitro and in vivo [51, 52].

To the best of our knowledge, this is the first clinical trial showing that intrahepatic cotransplantation of autologous MSCs with islets improves glycemic control and quality of life of IAT patients. Although only three patients have undergone this novel treatment approach, we did observe improvements in MSC patients compared with 101 matched historical patients.

CONCLUSION

Autologous MSC and islet cotransplantation may be a promising approach to improve the success rates of autologous islet transplantation and to enhance current autologous islet transplantation protocols. The results of this pilot study show that cotransplantation of MSC with islets may be a safe and feasible strategy to improve the efficacy of islet transplantation. This procedure can also serve as a platform to solve more complex allogeneic islet transplantation issues and treat patients with type 1 diabetes.

ACKNOWLEDGMENTS

We thank Dr. Jacque Galipeu (University of Wisconsin, Madison) for kindly offering human platelet lysate. We thank the Reeves family for their research support. This study was supported in part by the National Institutes of Health (EB015744, DK097544, DK105183, and DK099696 to H.W.). Dr. Nietert's work on this project was supported in part by the National Center for Advancing Translational Science (UL1 TR000062), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR062755), and the National Institute of General Medical Sciences (U54-GM104941). H.W. is the guarantor of this study and takes full responsibility for the work as a whole, including the study design, access to data, and the decision to submit and publish the manuscript.
AUTHOR CONTRIBUTIONS

H.W.: conception and design, performance of some of the study, data analysis and interpretation, manuscript writing; C.S.: data analysis and interpretation, manuscript writing; P.N.: conception and design, data analysis and interpretation, manuscript writing; J.W., C.C., S.O., T.D., B.S.: performance of the study; T.T.: data analysis and interpretation, manuscript writing; G.G., L.L.: conception and design; K.H., J.F.: evaluation of treatment safety; D.A., K.M.: performance of surgery, patient care, manuscript writing.

REFERENCES

1. Montañá E, Bonner-Weir S, Weir GC. Beta cell mass and growth after syngeneic islet cell transplantation in normal and streptozocin diabetic C57BL/6 mice. J Clin Invest 1993;91:780–787.
2. Davalli AM, Scaglia L, Zangen DH et al. Visceral obesity of the Willet in the immediate post-transplantation period. Dynamic changes in structure and function. Diabetes 1996;45:1161–1167.
3. Shapiro AM, Pokrywczynska M, Ricardi C. Clinical pancreatic islet transplantation. Nat Rev Endocrinol 2017;13:268–277.
4. Wang J, Sun G, Gou W et al. α1-antitrypsin enhances islet engraftment by suppression of instant blood-mediated inflammatory reaction. Diabetes 2017;66:970–980.
5. Naziruddin B, Iwashashi S, Kanak MA et al. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant 2014;14:428–437.
6. Sakata N, Hayes P, Tan A et al. MRI assessment of ischemic liver after intraportal islet transplantation. Transplantation 2009;87:825–830.
7. Ahmad SA, Lowy AM, Wray CJ et al. Factors associated with insulin and narcotic independence after islet autotransplantation in patients with severe chronic pancreatitis. J Am Coll Surg 2005;201:680–687.
8. Ryan EA, Paty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005;54:2060–2069.
9. Argo JL, Contreras JL, Wesley MM et al. Pancreatic resection with islet cell autotransplant for the treatment of severe chronic pancreatitis. Am Surg 2008;74:530–536; discussion 536–537.
10. Anazawa T, Balamurugan AN, Bellin M et al. Human islet isolation for autologous transplantation: Comparison of yield and function using SERVA/Nordmark versus Roche enzymes. Am J Transplant 2009;9:2383–2391.
11. Hering BJ, Kanas RH, Kin T et al. Human mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011;10:649–656.
12. Lee RH, Neo MJ, Reger RL et al. Multipotential stem cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 2006;103:17438–17443.
13. Uccelli A, Larini A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2010;13:993–1004.
14. Uccelli A, Larini A, Freedman MS. Mesenchymal stem cells prolong the survival of a semi-allogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008;181:3933–3946.
15. Fiorina P, Jurewicz M, Augello A et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009;183:993–1004.
16. Naziruddin B, Iwashashi S, Kanak MA et al. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant 2014;14:428–437.
17. Uccelli A, Larini A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011;10:649–656.
18. Lee RH, Neo MJ, Reger RL et al. Multipotential stem cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 2006;103:17438–17443.
19. Uccelli A, Larini A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2010;13:993–1004.
20. Naziruddin B, Iwashashi S, Kanak MA et al. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant 2014;14:428–437.
21. Sakata N, Hayes P, Tan A et al. MRI assessment of ischemic liver after intraportal islet transplantation. Transplantation 2009;87:825–830.
22. Ahmad SA, Lowy AM, Wray CJ et al. Factors associated with insulin and narcotic independence after islet autotransplantation in patients with severe chronic pancreatitis. J Am Coll Surg 2005;201:680–687.
23. Ryan EA, Paty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005;54:2060–2069.
24. Argo JL, Contreras JL, Wesley MM et al. Pancreatic resection with islet cell autotransplant for the treatment of severe chronic pancreatitis. Am Surg 2008;74:530–536; discussion 536–537.
25. Anazawa T, Balamurugan AN, Bellin M et al. Human islet isolation for autologous transplantation: Comparison of yield and function using SERVA/Nordmark versus Roche enzymes. Am J Transplant 2009;9:2383–2391.
26. Hering BJ, Kanas RH, Kin T et al. Human mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2010;13:993–1004.
27. Naziruddin B, Iwashashi S, Kanak MA et al. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant 2014;14:428–437.
28. Uccelli A, Larini A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011;10:649–656.
29. Lee RH, Neo MJ, Reger RL et al. Multipotential stem cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 2006;103:17438–17443.
30. Uccelli A, Larini A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2010;13:993–1004.
31. Naziruddin B, Iwashashi S, Kanak MA et al. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant 2014;14:428–437.
32. Uccelli A, Larini A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2010;13:993–1004.
33. Naziruddin B, Iwashashi S, Kanak MA et al. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant 2014;14:428–437.
34. Uccelli A, Larini A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2010;13:993–1004.
35. Naziruddin B, Iwashashi S, Kanak MA et al. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant 2014;14:428–437.
36. Uccelli A, Larini A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2010;13:993–1004.
37. Naziruddin B, Iwashashi S, Kanak MA et al. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant 2014;14:428–437.
38. Uccelli A, Larini A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2010;13:993–1004.
39. Naziruddin B, Iwashashi S, Kanak MA et al. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant 2014;14:428–437.
40. Uccelli A, Larini A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2010;13:993–1004.

NOTE ADDED IN PROOF

This article was published online on 21 November 2017. Minor edits have been made that do not affect data. This notice is included in the online and print versions to indicate that both have been corrected 28 December 2017.

DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The authors indicated no potential conflicts of interest.

© 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
40 Maiborodin IV, Morozov VV, Markevich YV et al. Acceleration of angiogenesis after paravasal injection of mesenchymal stem cells at the site of modeled venous thrombosis. Bull Exp Biol Med 2015;159:128–133.

41 Kawahara T, Kin T, Kashkoush S et al. Portal vein thrombosis is a potentially preventable complication in clinical islet transplantation. Am J Transplant 2011;11:2700–2707.

42 Cao M, Pan Q, Dong H et al. Adipose-derived mesenchymal stem cells improve glucose homeostasis in high-fat diet-induced obese mice. Stem Cell Res Ther 2015;6:208.

43 Siniscalco D, Giordano C, Galderisi U et al. Human mesenchymal stem cells as novel neuropathic pain tool. J Stem Cells Regen Med 2010;6:127.

44 Das AK, Bin Abdullah BJ, Dhillon SS et al. Intra-arterial allogeneic mesenchymal stem cells for critical limb ischemia are safe and efficacious: Report of a phase I study. World J Surg 2013;37:915–922.

45 Matsumoto S, Noguchi H, Takita M, Shimoda M, Tamura Y, Olsen G, Naziruddin B, Onaca N, Levy MF. Super-high-dose islet transplantation is associated with high SUITO index and prolonged insulin independence: a case report. Transplant Proc 2010;42:2156–2158.

46 Johnston PC, Lin YK, Walsh RM, Bottino R, Stevens TK, Trucco M, Bena J, Faiman C, Hatipoglu BA. Factors associated with islet yield and insulin independence after total pancreatectomy and islet cell autotransplantation in patients with chronic pancreatitis utilizing off-site islet isolation: Cleveland Clinic experience. J Clin Endocrinol Metab 2015;100:1765–1770.

47 Muroi K, Miyamura K, Okada M et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: A phase II/Ill study. Int J Hematol 2016;103:243–250.

48 Forbes GM, Sturm MJ, Leong RW et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy. Clin Gastroenterol Hepatol 2014;12:64–71.

49 Sun L, Akiyama K, Zhang H et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. STEM CELLS 2009;27:1421–1432.

50 Patel AN, Genovese J. Potential clinical applications of adult human mesenchymal stem cell (Prochymal®) therapy. Stem Cells Cloning 2011;4:61–72.

51 Khorsandi L, Nejad-Dehbashi F, Ahangarpour A et al. Three-dimensional differentiation of bone marrow-derived mesenchymal stem cells into insulin-producing cells. Tissue Cell 2015;47:66–72.

52 Haidara MA, Assiri AS, Youssef MA et al. Differentiated mesenchymal stem cells ameliorate cardiovascular complications in diabetic rats. Cell Tissue Res 2015;359:565–575.